

Table S2 Proportion of prescriptions of biological and conventional synthetic disease-modifying anti-rheumatic drugs as well as systemic steroids according to the care specialization of the prescriber.

	Rheumatologists	Gastroenterologists	Dermatologists	Ophthalmologists	Others/Unknown
bDMARDs	69.5%	3.9%	-	-	26.6%
mAb against TNF (adalimumab, golimumab, infliximab)	70.7%	4.9%	-	-	24.4%
Certolizumab pegol	66.7%	-	-	-	33.3%
Etanercept	67.5%	1.0%	-	-	31.5%
Secukinumab	100%	-	-	-	-
Ustekinumab	-	-	-	-	100%
Vedolizumab	-	100%	-	-	-
Other*	100%	-	-	-	-
csDMARDs	32.0%	7.8%	-	-	60.2%
Methotrexate	51.9 %	-	-	-	48.1%
Sulfasalazine	33.5%	3.0%	-	-	63.4%
Mesalazine	-	29.3%	-	-	70.7%
Azathioprine	5.5%	36.4%	-	-	67.3%
Leflunomide	32.7%	-	-	-	67.3%
Other**	19.6%	3.9%	-	-	76.5%
Systemic steroids	20.7%	2.8%	0.6%	0.8%	75.1%

*including abatacept, tocilizumab; **including mycophenolic acid, teriflunomide, ciclosporin, tacrolimus, lenalidomide.
bDMARDs, biological disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; mAb, monoclonal antibodies; TNF, tumor necrosis factor.